Ultrasound-Derived Fat Fraction Accurately Grades Steatosis in Chronic Liver Disease

The clinical challenge of quantifying hepatic steatosis

The global increase in metabolic dysfunction-associated steatotic liver disease, a condition characterized by hepatic fat accumulation linked to metabolic risk factors, has made it the most prevalent cause of chronic liver disease in Western nations [1]. While liver biopsy remains the historical reference standard for staging, its invasive nature and associated risks necessitate the development of reliable noninvasive biomarkers for routine clinical use [2, 3]. Accurate quantification of liver fat is particularly critical for patients with comorbid type 2 diabetes or obesity, who face significantly higher risks of progression to cirrhosis and hepatocellular carcinoma, or primary liver cancer [4, 5]. Current guidelines emphasize the need for accessible screening tools that can risk-stratify patients and monitor treatment response without the cost and access limitations of magnetic resonance imaging [6, 4]. A recent prospective multicenter study now offers fresh insights into the utility of a quantitative ultrasound technique for assessing hepatic steatosis, providing clinicians with a potential alternative to invasive tissue sampling.

Multicenter evaluation of ultrasound-derived fat fraction

To evaluate the diagnostic performance of ultrasound-derived fat fraction, a quantitative tool that measures the percentage of fat in liver tissue by analyzing ultrasound signal attenuation and backscatter, researchers conducted a prospective multicenter study between October 2024 and June 2025. The investigators utilized the DAX probe, a specialized deep-abdominal transducer designed to improve signal penetration in patients with high body mass index or difficult acoustic windows. The study population included 255 patients with chronic liver disease who had a mean age of 51.27 years (standard deviation of 11.24), and 148 participants (58.04%) were men. To establish a rigorous comparison, the researchers used liver biopsy as the reference standard for all participants, as this invasive procedure remains the definitive clinical method for assessing hepatic fat content and architectural changes. Among the 255 patients enrolled, histological analysis confirmed that 146 individuals (57.25%) had no steatosis, categorized as stage S0. The remaining patients presented with varying degrees of fat accumulation, allowing the authors to test the ability of the ultrasound-derived fat fraction to differentiate between healthy tissue and diseased states. By comparing these noninvasive measurements against biopsy results, the study aimed to determine if this technique could reliably grade hepatic steatosis across a diverse clinical population, potentially reducing the need for routine biopsies in practice.

Diagnostic accuracy and optimal cutoff values

The researchers evaluated the diagnostic performance of the ultrasound-derived fat fraction by calculating the area under the receiver-operating characteristic curve, a statistical measure where a value of 1.0 represents perfect diagnostic accuracy. For the detection of hepatic steatosis of grade S1 or higher, the study reported an area under the curve of 0.914 (95% confidence interval: 0.873 to 0.946). The diagnostic accuracy remained high for more advanced stages of fat accumulation, yielding an area under the curve of 0.950 (95% confidence interval: 0.916 to 0.974) for detecting steatosis of grade S2 or higher. For the most severe cases, categorized as grade S3 steatosis, the ultrasound-derived fat fraction achieved an area under the curve of 0.916 (95% confidence interval: 0.875 to 0.947). These figures indicate that the technology maintains strong discriminatory power across the entire spectrum of fatty liver severity when compared to the histological reference standard. To assist clinicians in practical application, the study identified specific percentage thresholds that correspond to histological grades. The optimal cutoff value for detecting hepatic steatosis of grade S1 or higher was 7%, a threshold that applied to 109 patients (42.75% of the cohort). For identifying moderate disease, the researchers determined an optimal cutoff value of 11% for grade S2 or higher, which was observed in 79 patients (30.98%). Finally, the optimal cutoff value for detecting grade S3 steatosis was 18%, a level found in 39 patients (15.30%). By establishing these clear numerical benchmarks, the findings suggest that clinicians can use these specific fat fraction percentages to stage disease severity noninvasively, facilitating quicker treatment decisions.

Performance across confounding clinical variables

A critical concern for clinicians using ultrasound-based tools is whether concurrent liver pathology or patient anatomy might interfere with the accuracy of fat quantification. To address this, the researchers evaluated several possible influencing factors, including the underlying etiology of the disease, the stage of necroinflammation (active liver cell death and inflammation), the degree of fibrosis (liver scarring), and various anthropometric indices (measurements of body size and proportions). The study found that the diagnostic performance of the ultrasound-derived fat fraction remained robust despite these variables. Specifically, in a subgroup of 164 patients with necroinflammation, the technology demonstrated an area under the curve greater than 0.9 for detecting hepatic steatosis of grade S1 or higher. This high level of accuracy was also maintained in the presence of advanced fibrosis (n = 61), where the area under the curve for detecting grade S1 or higher steatosis again exceeded 0.9, suggesting that significant scarring does not degrade the tool's ability to quantify fat. The researchers also examined how physical characteristics might impact the DAX probe's performance, focusing on the skin-to-capsule distance (the depth from the skin surface to the liver edge) and the intercostal distance (the width of the space between the ribs). In the 129 patients with a skin-to-capsule distance of 1.9 cm or greater, the ultrasound-derived fat fraction achieved an area under the curve greater than 0.9 for detecting grade S1 or higher steatosis. Similarly, for the 162 patients with an intercostal distance of 2.5 cm or less, the area under the curve remained above 0.9. These findings indicate that the measurement remains reliable even in patients with a thicker subcutaneous fat layer or narrower acoustic windows between the ribs, which are common challenges in traditional hepatic imaging. Finally, the study confirmed the utility of this modality across different disease origins beyond metabolic conditions. When the researchers excluded patients with isolated metabolic dysfunction-associated steatotic liver disease (n = 178), the area under the curve for detecting hepatic steatosis of grade S1 or higher remained greater than 0.9. This consistency across a mixed-etiology population suggests that the ultrasound-derived fat fraction is a versatile clinical tool, providing accurate fat grading regardless of whether the underlying chronic liver disease is driven by metabolic factors, viral hepatitis, or other causes.

Clinical implications for noninvasive monitoring

The study results indicate that the ultrasound-derived fat fraction measured with the DAX probe provides a reliable alternative to liver biopsy for quantifying hepatic steatosis in patients with chronic liver disease. By achieving an area under the curve of 0.914 (95% confidence interval: 0.873 to 0.946) for detecting grade S1 or higher steatosis, the technology allows for accurate diagnosis and timely monitoring without the bleeding risks or patient discomfort associated with invasive procedures. For practicing physicians, this means that the optimal cutoff values of 7% for grade S1 or higher (n = 109), 11% for grade S2 or higher (n = 79), and 18% for grade S3 (n = 39) can be used to categorize fat content with high precision at the point of care. These findings are particularly relevant for the longitudinal management of patients, as the high diagnostic performance across all grades, including an area under the curve of 0.950 (95% confidence interval: 0.916 to 0.974) for grade S2 or higher and 0.916 (95% confidence interval: 0.875 to 0.947) for grade S3, supports the use of this modality for tracking disease progression or response to weight loss and pharmacological interventions over time. A primary clinical takeaway is the robustness of the measurements against common confounding factors that often complicate liver imaging. The researchers concluded that ultrasound-derived fat fraction measured with the DAX probe detected and graded hepatic steatosis regardless of etiology, necroinflammation, fibrosis, or anthropometric indices. This is evidenced by the consistent area under the curve values exceeding 0.9 for detecting grade S1 or higher steatosis in diverse subgroups, including 164 patients with necroinflammation and 61 patients with advanced fibrosis. Furthermore, the tool remained accurate in 129 patients with a skin-to-capsule distance of 1.9 cm or greater and 162 patients with an intercostal distance of 2.5 cm or less, ensuring that patient body habitus does not significantly degrade diagnostic utility. By providing a stable assessment across 178 patients when excluding isolated metabolic dysfunction-associated steatotic liver disease, the study confirms that this technology is a versatile modality suitable for a broad spectrum of patients with chronic liver disease in a typical clinical practice.

References

1. Leoni S, Tovoli F, Napoli L, Serio I, Ferri S, Bolondi L. Current guidelines for the management of non-alcoholic fatty liver disease: A systematic review with comparative analysis. World Journal of Gastroenterology. 2018. doi:10.3748/wjg.v24.i30.3361

2. Rinella ME, Neuschwander‐Tetri BA, Siddiqui MS, et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023. doi:10.1097/hep.0000000000000323

3. Reeder SB, Yokoo T, França M, et al. Quantification of Liver Iron Overload with MRI: Review and Guidelines from the ESGAR and SAR. Radiology. 2023. doi:10.1148/radiol.221856

4. Tacke F, Horn P, Wong VW. EASL-EASD-EASO Clinical Practice Guidelines on the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). Obesity Facts. 2024. doi:10.1159/000539371

5. Cusi K, Abdelmalek MF, Apovian CM, et al. Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD) in People With Diabetes: The Need for Screening and Early Intervention. A Consensus Report of the American Diabetes Association. Diabetes Care. 2025. doi:10.2337/dci24-0094

6. Kavvadas D, Rafailidis V, Liakos A, et al. Quantitative Ultrasound for Hepatic Steatosis: A Systematic Review Highlighting the Diagnostic Performance of Ultrasound-Derived Fat Fraction.. Diagnostics (Basel, Switzerland). 2025. doi:10.3390/diagnostics15202640